Vemurafenib in Langerhans cell histiocytosis: report of a pediatric patient and review of the literature

Selective BRAF inhibitors such as vemurafenib have become a treatment option in patients with Langerhans cell Histiocytosis (LCH). To date, only 14 patients receiving vemurafenib for LCH have been reported. Although vemurafenib can stabilize the clinical condition of these patients, it does not seem...

Full beskrivning

Sparad:
Bibliografiska uppgifter
I publikationen:Oncotarget
Huvudupphovsmän: Heisig, Anne, Sörensen, Jan, Zimmermann, Stefanie-Yvonne, Schöning, Stefan, Schwabe, Dirk, Kvasnicka, Hans-Michael, Schwentner, Raphaela, Hutter, Caroline, Lehrnbecher, Thomas
Materialtyp: Artigo
Språk:Inglês
Publicerad: Impact Journals LLC 2018
Ämnen:
Case Report
Länkar:https://ncbi.nlm.nih.gov/pmc/articles/PMC5955145/
https://ncbi.nlm.nih.gov/pubmed/29774135
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.25277
Taggar: Lägg till en tagg
Inga taggar, Lägg till första taggen!

Liknande verk